Used as a key intermediate in the synthesis of potent PARP (poly ADP-ribose polymerase) inhibitors, this compound plays a critical role in the development of targeted cancer therapies. Its structure enables high binding affinity to the PARP enzyme, making it valuable in creating drugs that selectively inhibit DNA repair in cancer cells, particularly in BRCA-mutated tumors. It is employed in pharmaceutical research to develop analogs with improved metabolic stability and bioavailability. The compound's functional groups allow for further chemical modifications, facilitating structure-activity relationship studies during drug optimization.